No connection

Search Results

BIAF vs NXGL

BIAF
bioAffinity Technologies, Inc.
BEARISH
Price
$1.35
Market Cap
$6.1M
Sector
Healthcare
AI Confidence
95%
NXGL
NEXGEL, Inc.
BEARISH
Price
$0.76
Market Cap
$6.4M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
BIAF
--
NXGL
--
Forward P/E
BIAF
-2.25
NXGL
3.29
P/B Ratio
BIAF
0.52
NXGL
1.38
P/S Ratio
BIAF
0.9
NXGL
0.56
EV/EBITDA
BIAF
0.09
NXGL
-3.31

Profitability

Gross Margin
BIAF
27.86%
NXGL
39.48%
Operating Margin
BIAF
-158.56%
NXGL
-43.42%
Profit Margin
BIAF
-217.5%
NXGL
-26.27%
ROE
BIAF
-245.18%
NXGL
-52.74%
ROA
BIAF
-71.71%
NXGL
-19.54%

Growth

Revenue Growth
BIAF
-38.5%
NXGL
-8.1%
Earnings Growth
BIAF
--
NXGL
--

Financial Health

Debt/Equity
BIAF
0.08
NXGL
0.63
Current Ratio
BIAF
3.65
NXGL
1.47
Quick Ratio
BIAF
3.44
NXGL
0.34

Dividends

Dividend Yield
BIAF
--
NXGL
--
Payout Ratio
BIAF
0.0%
NXGL
0.0%

AI Verdict

BIAF BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a seemingly healthy Current Ratio of 3.65 and low Debt/Equity of 0.08, the company is deeply unprofitable, with a Profit Margin of -217.50% and ROE of -245.18%. Revenue has collapsed by 38.5% year-over-year, and the stock has lost nearly all value over the past five years, down 99.5%. While the recent 1-month price increase of +9.8% may suggest speculative momentum, fundamentals remain abysmal, and the lack of analyst coverage or target prices underscores minimal market confidence.

Strengths
Strong liquidity position with Current Ratio of 3.65 and Quick Ratio of 3.44
Low leverage with Debt/Equity ratio of only 0.08
Positive gross margin of 27.86%, indicating some pricing power or cost control at production level
Risks
Critically low Piotroski F-Score of 1/9 signals high risk of financial failure
Massive and sustained profitability deficits: Operating Margin of -158.56%, ROA of -71.71%
Revenue declining sharply by 38.5% year-over-year, indicating deteriorating business fundamentals
NXGL BEARISH

NXGL exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. The company suffers from chronic profitability issues, with negative operating margins (-43.42%) and a consistent track record of missing earnings estimates (0/4 beats in the last year). Revenue is shrinking both YoY and Q/Q, while the stock has plummeted over 73% in the last year. Combined with bearish insider selling by the CEO, the outlook is highly precarious.

Strengths
Positive gross margin of 39.48%
Manageable Debt/Equity ratio of 0.63
Current ratio of 1.47 suggests short-term solvency
Risks
Critical fundamental health (Piotroski 1/9)
Negative revenue growth (-8.10% YoY)
Severe liquidity risk indicated by a low Quick Ratio (0.34)

Compare Another Pair

BIAF vs NXGL: Head-to-Head Comparison

This page compares bioAffinity Technologies, Inc. (BIAF) and NEXGEL, Inc. (NXGL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile